Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.
FDA grants bioMérieux dual clearance and CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis Panel, a rapid 20-minute ...
Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its breast cancer genomic testing portfolio, the ...
Illumina has introduced three early-access software capabilities on its BioInsight Platform designed to automate informatics ...
Gene by Gene will provide whole-genome sequencing for Children’s Mercy’s program, targeting nearly 100,000 pediatric genomes.
Hologic and Inpeco have partnered to connect Panther Systems with FlexLab X automation in Europe, aiming to improve ...
A study finds permissive lab screening thresholds double primary aldosteronism detection rates versus Endocrine Society ...
Quest Diagnostics and Waters will expand at-home HPV screening in 2027, offering extended genotyping via the Onclarity ...
A study reports that liquid biopsy tests can detect early lung cancer recurrence months before imaging in NSCLC patients.
Biodesix, in partnership with Bio-Rad and Thermo Fisher Scientific, advances tumor-informed and tumor-naïve MRD assays for ...
Medicare now reimburses Lucid Diagnostics’ EsoGuard esophageal DNA test at $1,938 per test, following its $15 million private placement.
Guardant Health and partners will present 25 abstracts on liquid biopsy advances for cancer monitoring at ESMO 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results